 Doses may be delayed because of neutropenia, thrombocytopenia, or other side effects.A FDG PET scan is commonly advised following the completion of ABVD to assess response to therapy.Interim PET (following 2 cycles) may be useful in aiding prognostication, but does not yet guide changes in therapy except within clinical trial protocols.